Macrophages Help Cancer Cells Resist Ferroptosis Through PRDX6 Protein Transfer
New study reveals how immune cells in tumors deliver protective proteins that block a promising cancer treatment approach.
Summary
Researchers discovered that macrophages in the tumor environment help cancer cells resist ferroptosis, a type of cell death being explored as a cancer treatment. The immune cells transfer a protein called PRDX6 through tiny vesicles, which protects cancer cells from oxidative damage. This finding explains why some cancers resist ferroptosis-inducing drugs and suggests new therapeutic targets.
Detailed Summary
Ferroptosis represents a promising new approach to cancer treatment, triggering cancer cell death through iron-dependent oxidative damage. However, many tumors develop resistance to ferroptosis-inducing drugs, limiting their therapeutic potential.
Researchers at Shanghai Jiao Tong University investigated how tumor-associated macrophages contribute to this resistance. They co-cultured various cancer cell lines with different types of macrophages and tested responses to ferroptosis inducers like RSL3 and erastin. Using RNA sequencing and proteomic analysis, they identified key molecular mechanisms.
The study revealed that macrophages consistently protected cancer cells from GPX4 inhibitor-induced ferroptosis across multiple cell lines. This protection occurred through direct cell contact and delivery of macrophage-derived extracellular vesicles enriched with PRDX6 protein. PRDX6 acted as a glutathione peroxidase, reducing mitochondrial superoxide levels by 40-60% and preventing the mitophagy that normally accompanies ferroptosis.
In mouse tumor models, depleting macrophages with clodronate liposomes enhanced RSL3 efficacy, while PRDX6-knockout mice showed increased tumor sensitivity to ferroptosis induction. Conversely, injecting PRDX6-rich extracellular vesicles into tumors promoted resistance and tumor growth.
These findings reveal a novel mechanism of cancer drug resistance and suggest that targeting macrophages or PRDX6 could enhance ferroptosis-based cancer therapies. However, the study was limited to mouse models and specific cancer cell lines, requiring validation in human tumors.
Key Findings
- Macrophages reduced GPX4 inhibitor-induced lipid peroxidation across multiple cancer cell lines
- PRDX6 protein levels were 3-5 fold higher in macrophage-derived extracellular vesicles compared to cancer cells
- PRDX6 overexpression reduced mitochondrial superoxide levels by 40-60% in ferroptosis-treated cells
- Macrophage depletion with clodronate liposomes enhanced RSL3 anti-tumor efficacy in mouse models
- PRDX6-knockout mice showed increased tumor sensitivity to 8 mg/kg RSL3 compared to 40 mg/kg in wild-type mice
- Intratumoral injection of PRDX6-rich extracellular vesicles promoted tumor growth and ferroptosis resistance
- PRDX6 glutathione peroxidase activity increased cellular GSH/GSSG ratios by 2-3 fold during ferroptosis stress
Methodology
The study used mouse MC38 colon carcinoma, B16-F10 melanoma, and CT26 colon cancer cell lines co-cultured with bone marrow-derived macrophages. Researchers employed RNA sequencing, proteomic analysis, and flow cytometry to assess ferroptosis markers. In vivo experiments used C57BL/6J mice with subcutaneous tumors treated with RSL3 and various interventions over 12-19 days. Statistical analysis included Student's t-tests and one-way ANOVA with appropriate post-hoc tests.
Study Limitations
The study was conducted primarily in mouse models and specific cancer cell lines, requiring validation in human tumors and diverse cancer types. The research focused on M2-like macrophages, but tumor-associated macrophages show significant heterogeneity in human cancers. Long-term effects of targeting PRDX6 or macrophages in combination with ferroptosis inducers were not evaluated. No conflicts of interest were reported.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.